Updated Jul 16, 2026
Doyle Mittie has filed 8 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $2.91M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 4.7K | $20.00 | $93K |
| 2026-07-02 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 1.8K | $8.04 | $14K |
| 2026-07-02 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 2.9K | $12.65 | $36K |
| 2026-06-25 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 1.4K | $18.00 | $26K |
| 2026-06-25 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 1.4K | $8.04 | $12K |
| 2026-06-12 | AVTX | Avalo Therapeutics, Inc. | F — Tax withholding / forfeiture | 1.1K | $13.10 | $14K |
| 2026-06-01 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 679 | $16.00 | $11K |
| 2026-06-01 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 679 | $8.04 | $5K |
| 2026-05-26 | AVTX | Avalo Therapeutics, Inc. | A — Grant or award | 43.5K | $0.00 | |
| 2026-05-19 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 3.0K | $18.76 | $56K |
| 2026-05-19 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 3.0K | $12.65 | $38K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 10.1K | $22.88 | $230K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 19.0K | $22.41 | $426K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 44.9K | $21.20 | $953K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 5.0K | $19.65 | $98K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 27.5K | $18.03 | $496K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 28.6K | $8.04 | $230K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 77.9K | $12.65 | $985K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 1.7K | $16.00 | $27K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 679 | $8.04 | $5K |
Doyle Mittie is a corporate insider — currently tracked as Insider of Avalo Therapeutics, Inc. (AVTX). InsiderAlpha tracks every SEC Form 4 filing in real time.
8 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($2.91M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Doyle Mittie profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.